Symbols / MANE Stock $101.00 +2.02% Veradermics, Incorporated

Healthcare • Biotechnology • United States • NYQ
MANE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Reid Waldman M.D.
Exch · Country NYQ · United States
Market Cap 4.16B
Enterprise Value 3.90B
Income -83.37M
Sales —
FCF (ttm) -47.55M
Book/sh -163.87
Cash/sh 3.80
Employees —
Insider 10d —
IPO Feb 04, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -33.64
PEG —
P/S —
P/B -0.62
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 15.64
Current Ratio 16.66
Debt/Eq 0.00
LT Debt/Eq —
EPS (ttm) -2.37
EPS next Y -3.00
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) —
ROA -43.45%
ROE -72.06%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 41.18M
Shs Float 20.38M
Insider Own 2.78%
Instit Own 50.74%
Short Float 7.86%
Short Ratio 3.36
Short Interest 1.79M
52W High 114.50
vs 52W High -11.79%
52W Low 32.00
vs 52W Low 215.62%
Beta —
Impl. Vol. —
Rel Volume 1.84
Avg Volume 541.02K
Volume 995.54K
Target (mean) $116.00
Tgt Median $120.00
Tgt Low $90.00
Tgt High $138.00
# Analysts 3
Recom Strong_buy
Prev Close $99.00
Price $101.00
Change 2.02%
About

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$116.00
Mean price target
2. Current target
$101.00
Latest analyst target
3. DCF / Fair value
$-20.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$101.00
Low
$90.00
High
$138.00
Mean
$116.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 main Leerink Partners Outperform → Outperform $90
2026-03-02 init Cantor Fitzgerald — → Overweight —
2026-03-02 init Citigroup — → Buy $85
2026-03-02 init Leerink Partners — → Outperform $75
2026-03-02 init Jefferies — → Buy $75
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-06 SUVRETTA CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security — 282,674 $34.25 $10,542,478
2026-02-05 CHILDS JOHN W Director — 294,117 $37.16 $10,929,388
2026-02-05 CHILDS JOHN W Director — 1,907,889 — —
2026-02-05 CHILDS JOHN W Director — 294,117 $37.16 $10,929,388
2026-02-05 CHILDS JOHN W Director — 1,907,889 — —
2026-02-05 ENRIGHT PATRICK G. Director and Beneficial Owner of more than 10% of a Class of Security — 1,075,000 $37.75 $40,581,250
2026-02-05 ENRIGHT PATRICK G. Director and Beneficial Owner of more than 10% of a Class of Security — 3,578,873 — —
2026-02-05 CORIC VLADIMIR Director — 117,646 $37.16 $4,371,725
2026-02-05 CORIC VLADIMIR Director — 638,262 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
71.56
+171.21%
26.38
+52.30%
17.32
Research And Development
62.06
+166.57%
23.28
+55.52%
14.97
Selling General And Administration
10.28
+194.19%
3.50
+48.53%
2.35
General And Administrative Expense
10.28
+194.19%
3.50
+48.53%
2.35
Other Gand A
10.28
+194.19%
3.50
+48.53%
2.35
Other Operating Expenses
-0.79
-100.51%
-0.39
—
Total Expenses
71.56
+171.21%
26.38
+52.30%
17.32
Operating Income
-71.56
-171.21%
-26.38
-52.30%
-17.32
Total Operating Income As Reported
-72.35
-170.17%
-26.78
-54.57%
-17.32
EBITDA
-70.00
-170.22%
-25.90
-57.43%
-16.45
Normalized EBITDA
-70.00
-170.22%
-25.90
-57.43%
-16.45
EBIT
-70.00
-170.22%
-25.90
-57.43%
-16.45
Net Income
-70.00
-164.25%
-26.49
-60.63%
-16.49
Pretax Income
-70.00
-164.25%
-26.49
-60.63%
-16.49
Net Non Operating Interest Income Expense
1.56
+1601.92%
-0.10
-112.47%
0.83
Interest Expense Non Operating
0.00
-100.00%
0.58
+1525.00%
0.04
Net Interest Income
1.56
+1601.92%
-0.10
-112.47%
0.83
Interest Expense
0.00
-100.00%
0.58
+1525.00%
0.04
Interest Income Non Operating
1.56
+224.74%
0.48
-44.71%
0.87
Interest Income
1.56
+224.74%
0.48
-44.71%
0.87
Tax Provision
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-70.00
-164.25%
-26.49
-60.63%
-16.49
Net Income From Continuing Operation Net Minority Interest
-70.00
-164.25%
-26.49
-60.63%
-16.49
Net Income From Continuing And Discontinued Operation
-70.00
-164.25%
-26.49
-60.63%
-16.49
Net Income Continuous Operations
-70.00
-164.25%
-26.49
-60.63%
-16.49
Normalized Income
-70.00
-164.25%
-26.49
-60.63%
-16.49
Net Income Common Stockholders
-83.37
-205.36%
-27.30
-65.57%
-16.49
Diluted EPS
-2.38
-73.30%
-1.37
+9.17%
-1.51
Basic EPS
-2.38
-73.30%
-1.37
+9.17%
-1.51
Basic Average Shares
35.08
+76.21%
19.91
+44.21%
13.80
Diluted Average Shares
35.08
+76.21%
19.91
+44.21%
13.80
Diluted NI Availto Com Stockholders
-83.37
-205.36%
-27.30
-65.57%
-16.49
Preferred Stock Dividends
13.38
+1541.47%
0.81
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
152.62
+174.82%
55.53
+216.22%
17.56
Current Assets
152.49
+174.59%
55.53
+216.22%
17.56
Cash Cash Equivalents And Short Term Investments
141.86
+167.24%
53.08
+225.75%
16.30
Cash And Cash Equivalents
21.77
-59.00%
53.08
+225.75%
16.30
Other Short Term Investments
120.10
0.00
—
Receivables
1.25
-8.73%
1.38
0.00
Taxes Receivable
1.25
-8.73%
1.38
0.00
Prepaid Assets
5.61
+440.37%
1.04
-14.92%
1.22
Current Deferred Assets
3.39
0.00
—
Other Current Assets
0.38
+902.63%
0.04
-17.39%
0.05
Total Non Current Assets
0.12
0.00
0.00
Net PPE
0.12
0.00
—
Gross PPE
0.12
0.00
—
Other Properties
0.12
—
—
Total Liabilities Net Minority Interest
273.63
+163.07%
104.02
+161.32%
39.80
Current Liabilities
9.15
+93.98%
4.72
+54.59%
3.05
Payables And Accrued Expenses
9.11
+92.98%
4.72
+54.59%
3.05
Payables
2.13
-5.43%
2.25
+21.38%
1.85
Accounts Payable
2.13
-5.43%
2.25
+21.38%
1.85
Current Accrued Expenses
6.98
+182.55%
2.47
+105.83%
1.20
Other Current Liabilities
0.05
—
—
Total Non Current Liabilities Net Minority Interest
264.48
+166.35%
99.30
+170.18%
36.75
Long Term Debt And Capital Lease Obligation
0.00
0.00
-100.00%
0.79
Long Term Debt
—
—
0.79
Long Term Capital Lease Obligation
0.00
0.00
—
Preferred Securities Outside Stock Equity
264.48
+166.35%
99.30
+176.09%
35.97
Stockholders Equity
-121.01
-149.62%
-48.48
-117.97%
-22.24
Common Stock Equity
-121.01
-149.62%
-48.48
-117.97%
-22.24
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
35.08
+0.00%
35.08
+0.00%
35.08
Ordinary Shares Number
35.08
+0.00%
35.08
+0.00%
35.08
Additional Paid In Capital
2.35
+212.80%
0.75
+50.00%
0.50
Retained Earnings
-123.42
-150.70%
-49.23
-116.47%
-22.74
Gains Losses Not Affecting Retained Earnings
0.06
0.00
—
Other Equity Adjustments
0.06
—
—
Total Equity Gross Minority Interest
-121.01
-149.62%
-48.48
-117.97%
-22.24
Total Capitalization
-121.01
-149.62%
-48.48
-125.95%
-21.46
Working Capital
143.34
+182.07%
50.82
+250.22%
14.51
Invested Capital
-121.01
-149.62%
-48.48
-125.95%
-21.46
Total Debt
0.00
0.00
-100.00%
0.79
Capital Lease Obligations
0.00
0.00
—
Net Tangible Assets
-121.01
-149.62%
-48.48
-117.97%
-22.24
Tangible Book Value
-121.01
-149.62%
-48.48
-117.97%
-22.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-71.60
-202.27%
-23.69
-75.34%
-13.51
Cash Flow From Continuing Operating Activities
-71.60
-202.27%
-23.69
-75.34%
-13.51
Net Income From Continuing Operations
-70.00
-164.25%
-26.49
-60.63%
-16.49
Other Non Cash Items
0.84
-53.85%
1.82
-1.94%
1.85
Stock Based Compensation
1.44
+476.00%
0.25
+21.36%
0.21
Change In Working Capital
-3.89
-630.87%
0.73
-20.43%
0.92
Change In Prepaid Assets
-8.23
-594.94%
-1.19
-20.55%
-0.98
Change In Payables And Accrued Expense
4.39
+128.90%
1.92
+0.74%
1.90
Change In Accrued Expense
4.51
+254.84%
1.27
+131.51%
0.55
Change In Payable
-0.12
-118.89%
0.65
-52.29%
1.35
Change In Account Payable
-0.12
-118.89%
0.65
-52.29%
1.35
Change In Other Current Liabilities
-0.04
0.00
—
Investing Cash Flow
-118.86
0.00
—
Cash Flow From Continuing Investing Activities
-118.86
0.00
—
Net PPE Purchase And Sale
-0.02
0.00
—
Purchase Of PPE
-0.02
0.00
—
Capital Expenditure
-0.02
—
—
Net Investment Purchase And Sale
-118.83
0.00
—
Purchase Of Investment
-143.85
0.00
—
Sale Of Investment
25.02
0.00
—
Financing Cash Flow
159.14
+163.15%
60.48
+335.24%
13.89
Cash Flow From Continuing Financing Activities
159.14
+163.15%
60.48
+335.24%
13.89
Net Issuance Payments Of Debt
0.00
-100.00%
7.66
0.00
Issuance Of Debt
0.00
-100.00%
8.51
0.00
Repayment Of Debt
0.00
+100.00%
-0.84
0.00
Long Term Debt Issuance
0.00
-100.00%
8.51
0.00
Long Term Debt Payments
0.00
+100.00%
-0.84
0.00
Net Long Term Debt Issuance
0.00
-100.00%
7.66
0.00
Proceeds From Stock Option Exercised
0.16
0.00
—
Net Other Financing Charges
-0.45
-57.95%
-0.28
-708.57%
-0.04
Changes In Cash
-31.32
-185.13%
36.79
+9455.32%
0.39
Beginning Cash Position
53.08
+225.75%
16.30
+2.42%
15.91
End Cash Position
21.77
-59.00%
53.08
+225.75%
16.30
Free Cash Flow
-71.63
-202.37%
-23.69
-75.34%
-13.51
Interest Paid Supplemental Data
0.00
-100.00%
0.10
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
Issuance Of Capital Stock
159.43
+200.27%
53.10
+281.17%
13.93
Net Preferred Stock Issuance
159.43
+200.27%
53.10
+281.17%
13.93
Preferred Stock Issuance
159.43
+200.27%
53.10
+281.17%
13.93
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category